CO2020001242A2 - Dihidrooxadiazinonas - Google Patents

Dihidrooxadiazinonas

Info

Publication number
CO2020001242A2
CO2020001242A2 CONC2020/0001242A CO2020001242A CO2020001242A2 CO 2020001242 A2 CO2020001242 A2 CO 2020001242A2 CO 2020001242 A CO2020001242 A CO 2020001242A CO 2020001242 A2 CO2020001242 A2 CO 2020001242A2
Authority
CO
Colombia
Prior art keywords
compounds
preparation
pharmaceutical compositions
diseases
dihydrooxadiazinones
Prior art date
Application number
CONC2020/0001242A
Other languages
English (en)
Inventor
Philip Lienau
Manuel Ellermann
Adrian Tersteegen
Stefan Nikolaus Gradl
Charlotte Christine Kopitz
Martin Lange
Christa Hegele-Hartung
Detlev Sülzle
Timothy A Lewis
Heidi Greulich
Xiaoyun Wu
Matthew Meyerson
Alex Burgin
Original Assignee
Dana Farber Cancer Inst Inc
Bayer Pharma AG
Bayer Ag
Broad Inst Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dana Farber Cancer Inst Inc, Bayer Pharma AG, Bayer Ag, Broad Inst Inc filed Critical Dana Farber Cancer Inst Inc
Publication of CO2020001242A2 publication Critical patent/CO2020001242A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D273/00—Heterocyclic compounds containing rings having nitrogen and oxygen atoms as the only ring hetero atoms, not provided for by groups C07D261/00 - C07D271/00
    • C07D273/02—Heterocyclic compounds containing rings having nitrogen and oxygen atoms as the only ring hetero atoms, not provided for by groups C07D261/00 - C07D271/00 having two nitrogen atoms and only one oxygen atom
    • C07D273/04—Six-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines having two or more nitrogen atoms in the same ring, e.g. oxadiazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/10—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Catalysts (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

Abstract

La invención proporciona compuestos de dihidrooxidiazinona de la fórmula general (I): (I), en donde R1, R2, R3, y R4 son como se definen en el presente, procedimientos para la preparación de dichos compuestos, compuestos intermedios útiles para la preparación de dichos compuestos, composiciones farmacéuticas y combinaciones que comprenden dichos compuestos y el uso de dichos compuestos para la elaboración de composiciones farmacéuticas para el tratamiento o la profilaxis de enfermedades, en especial de enfermedades hiperproliferativas, como un único agente o en combinación con otros ingredientes activos.
CONC2020/0001242A 2017-08-04 2020-02-04 Dihidrooxadiazinonas CO2020001242A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762541627P 2017-08-04 2017-08-04
PCT/EP2018/071039 WO2019025562A1 (en) 2017-08-04 2018-08-02 DIHYDROOXADIAZINONES

Publications (1)

Publication Number Publication Date
CO2020001242A2 true CO2020001242A2 (es) 2020-02-18

Family

ID=63207725

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2020/0001242A CO2020001242A2 (es) 2017-08-04 2020-02-04 Dihidrooxadiazinonas

Country Status (25)

Country Link
US (3) US11427553B2 (es)
EP (1) EP3661517B1 (es)
JP (2) JP2020529439A (es)
KR (1) KR20200036914A (es)
CN (1) CN111212647B (es)
AR (1) AR112402A1 (es)
AU (1) AU2018309356B2 (es)
BR (1) BR112020002351A2 (es)
CA (1) CA3071800A1 (es)
CL (1) CL2020000303A1 (es)
CO (1) CO2020001242A2 (es)
CR (1) CR20200057A (es)
CU (1) CU24608B1 (es)
EA (1) EA202090448A1 (es)
EC (1) ECSP20008441A (es)
IL (1) IL272098B2 (es)
JO (1) JOP20200024A1 (es)
MA (1) MA49750A (es)
MX (1) MX2020001404A (es)
PH (1) PH12020500134A1 (es)
SG (1) SG11201913775UA (es)
TW (1) TWI791581B (es)
UA (1) UA125731C2 (es)
UY (1) UY37832A (es)
WO (1) WO2019025562A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3661917B1 (en) 2017-08-04 2022-05-11 Bayer Aktiengesellschaft 6-((3-trifluoromethyl)phenyl)-4,5-dihydropyridazin-3(2h)-one derivatives as pde3a and pde3b inhibitors for treating cancer
JOP20200024A1 (ar) 2017-08-04 2020-02-02 Bayer Ag مركبات ثنائي هيدروكساديازينون
WO2020157188A1 (en) * 2019-02-01 2020-08-06 Bayer Aktiengesellschaft Dihydrooxadiazinones for the treatment of hyperproliferative diseases
CN117279644A (zh) 2021-03-03 2023-12-22 拜耳股份有限公司 用于治疗肉瘤的取代的3,6-二氢-2h-1,3,4-噁二嗪-2-酮
EP4289828A1 (en) 2022-06-10 2023-12-13 Bayer Aktiengesellschaft Method for the preparation of a 3,6-dihydro-2h-1,3,4-oxadiazin-2-one
EP4289829A1 (en) 2022-06-10 2023-12-13 Bayer Aktiengesellschaft Crystalline forms of (6s)-5-[4'-fluoro-2-(trifluoromethyl)biphenyl-4-yl]-6-methyl-3,6-dihydro- 2h-1,3,4-oxadiazin-2-one
WO2024109919A1 (zh) * 2022-11-24 2024-05-30 盛睿泽华医药科技（苏州）有限公司 吡啶酮化合物及其制备方法和用途
CN117903077A (zh) * 2023-01-13 2024-04-19 上海超阳药业有限公司 二氢噁二嗪酮化合物及其应用

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4097671A (en) * 1975-08-28 1978-06-27 General Electric Company Dihydrooxadiazinones and method for making
US4052395A (en) 1975-09-11 1977-10-04 Sankyo Company Limited Agricultural fungicidal compositions containing 6-(substituted phenyl)-pyridazinones and said pyridazinones
US4258094A (en) * 1979-04-26 1981-03-24 Brunswick Corporation Melt bonded fabrics and a method for their production
US4334030A (en) 1979-11-23 1982-06-08 General Electric Company Thermoplastic foamable blends
DE3172252D1 (en) 1980-11-14 1985-10-17 Ici Plc Heterocyclic compounds
FI72718C (fi) 1981-03-04 1987-07-10 Ciba Geigy Ag Foerfarande foer framstaellning av terapeutiskt verkande, substituerade 6-(4-morfolino-fenyl)-4,5-dihydro- 3(2h)-pyridazinoner och deras syraadditionssalter.
ZA827641B (en) 1981-11-12 1983-09-28 Ici Plc Thiadiazine, oxadiazine and triazine derivatives which possess cardiotonic and/or antihypertensive activity
US4495185A (en) 1981-11-12 1985-01-22 Imperial Chemical Industries, Plc 1,2,4-Triazin-3(2H) ones
US4581356A (en) 1983-03-22 1986-04-08 Fujisawa Pharmaceutical Co., Ltd. Triazine derivatives, and pharmaceutical compositions comprising the same
GB8310435D0 (en) 1983-04-18 1983-05-25 Fujisawa Pharmaceutical Co Triazine derivatives
JPS59196874A (ja) 1983-04-22 1984-11-08 Fujisawa Pharmaceut Co Ltd トリアジン誘導体
JPS6153270A (ja) 1984-08-17 1986-03-17 チバ・ガイギー・アクチエンゲゼルシヤフト 置換ピリダジノン、その製造方法及び該化合物を含む医薬製剤
US4816454A (en) 1984-09-21 1989-03-28 Cassella Aktiengesellschaft 4,5-dihydro-3(2H)-pyridazinones and their pharmacological use
GB8426804D0 (en) 1984-10-23 1984-11-28 Ciba Geigy Ag Pyridazinones preparations
ZW20586A1 (en) 1985-10-17 1988-05-25 Smith Kline French Lab Chemical compounds
EP0303418A3 (en) 1987-08-11 1990-11-07 Smithkline Beecham Laboratoires Pharmaceutiques Substituted indolones, useful in the treatment of heart or asthmatic diseases
EP0478195B1 (en) 1990-09-21 1999-05-26 Rohm And Haas Company Dihydropyridazinones and pyridazinones as fungicides
JPH0676325B2 (ja) * 1992-05-08 1994-09-28 三井東圧化学株式会社 オキサジアジン誘導体を有効成分として含有する抗血栓剤
BR9306661A (pt) 1992-07-01 1998-12-08 Ortho Pharma Corp 1-arilsulfonil arilcarbonil E 1-arilfosfonil-3-fenil 1,4,5,6-tetra-hidropidazinas
JPH07291968A (ja) 1994-04-26 1995-11-07 Mitsubishi Chem Corp トリアジノン誘導体またはその塩類
DE19929787A1 (de) * 1999-06-29 2001-01-04 Bayer Ag Neue 4-(2-Oxodihydrooxadiazinylphenyl)amide und ihre Verwendung
WO2002072103A1 (en) 2001-02-12 2002-09-19 Merck Patent Gmbh Use of type 4 phosphodiesterase inhibitors in myocardial diseases
WO2008108602A1 (en) 2007-03-07 2008-09-12 Dong-A Pharm. Co., Ltd. Novel phenylpropionic acid derivatives as peroxisome proliferator-activated gamma receptor modulators, method of the same, and pharmaceutical composition comprising the same
US9212146B2 (en) 2008-03-18 2015-12-15 Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences Substituted pyridazinones for the treatment of tumors
CN101538245B (zh) 2008-03-18 2011-02-16 中国科学院上海药物研究所 一类哒嗪酮类化合物及其制备方法和制备药物的用途
CA2758774C (en) 2009-04-15 2015-02-03 Research Triangle Institute Monoamine reuptake inhibitors
FR2948940B1 (fr) * 2009-08-04 2011-07-22 Servier Lab Nouveaux derives dihydroindolones, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
EP2566864B1 (en) 2010-05-07 2014-09-03 Boehringer Ingelheim International GmbH Pyridazinones as gpr119 agonists
WO2012112363A1 (en) 2011-02-14 2012-08-23 Merck Sharp & Dohme Corp. Cathepsin cysteine protease inhibitors
TWI532742B (zh) 2011-02-28 2016-05-11 艾伯維有限公司 激酶之三環抑制劑
WO2014164704A2 (en) 2013-03-11 2014-10-09 The Broad Institute, Inc. Compounds and compositions for the treatment of cancer
TWI656121B (zh) * 2014-08-04 2019-04-11 德商拜耳製藥公司 ２－（嗎啉－４－基）－１，７－萘啶
US11207320B2 (en) 2015-08-13 2021-12-28 The Broad Institute, Inc. Compositions and methods for cancer expressing PDE3A or SLFN12
JP6873145B2 (ja) 2016-01-14 2021-05-19 バイエル・ファルマ・アクティエンゲゼルシャフト ５−置換２−（モルホリン−４−イル）−１，７−ナフチリジン
CN114601837A (zh) 2016-02-05 2022-06-10 拜耳医药股份公司 用于癌症患者分级和癌症治疗的化合物、组合物和方法
KR101831772B1 (ko) * 2016-03-24 2018-03-06 아이디에스(주) 복합 광원 모듈을 가지는 카메라 접사용 기구 및 이를 이용한 지문 시편 촬영 방법
TWI794171B (zh) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療
TWI808055B (zh) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Hdac 抑制劑與 pd-1 抑制劑之組合治療
JOP20200024A1 (ar) 2017-08-04 2020-02-02 Bayer Ag مركبات ثنائي هيدروكساديازينون
EP3661917B1 (en) 2017-08-04 2022-05-11 Bayer Aktiengesellschaft 6-((3-trifluoromethyl)phenyl)-4,5-dihydropyridazin-3(2h)-one derivatives as pde3a and pde3b inhibitors for treating cancer
WO2020092998A1 (en) 2018-11-01 2020-05-07 The Broad Institute, Inc. Identification of pde3 modulator responsive cancers
AR117929A1 (es) 2019-02-01 2021-09-01 Bayer Ag Compuestos de 1,2,4-triazin-3(2h)-ona

Also Published As

Publication number Publication date
TWI791581B (zh) 2023-02-11
CA3071800A1 (en) 2019-02-07
AU2018309356A1 (en) 2020-01-30
CL2020000303A1 (es) 2020-11-13
BR112020002351A2 (pt) 2020-09-08
JP2023115065A (ja) 2023-08-18
EP3661517B1 (en) 2023-09-13
MA49750A (fr) 2020-06-10
CR20200057A (es) 2020-06-16
CN111212647B (zh) 2024-05-14
KR20200036914A (ko) 2020-04-07
US11773070B2 (en) 2023-10-03
EA202090448A1 (ru) 2020-05-21
UA125731C2 (uk) 2022-05-25
CU20200008A7 (es) 2020-11-30
US20200369633A1 (en) 2020-11-26
MX2020001404A (es) 2020-03-12
ECSP20008441A (es) 2020-05-29
IL272098B1 (en) 2023-03-01
US20230017200A1 (en) 2023-01-19
AU2018309356B2 (en) 2022-12-15
EP3661517A1 (en) 2020-06-10
WO2019025562A1 (en) 2019-02-07
IL272098B2 (en) 2023-07-01
JOP20200024A1 (ar) 2020-02-02
PH12020500134A1 (en) 2021-01-25
US20220396554A1 (en) 2022-12-15
JP2020529439A (ja) 2020-10-08
TW201917126A (zh) 2019-05-01
UY37832A (es) 2019-02-28
CN111212647A (zh) 2020-05-29
SG11201913775UA (en) 2020-01-30
US11427553B2 (en) 2022-08-30
CU24608B1 (es) 2022-06-06
IL272098A (en) 2020-03-31
AR112402A1 (es) 2019-10-23

Similar Documents

Publication Publication Date Title
ECSP19030002A (es) 1,2,4-triazolonas 2,4,5-trisustituidas
DOP2018000226A (es) Nuevos derivados de pirazolopirimidina
DOP2019000117A (es) Nuevos derivados de quinolina
CO2020001242A2 (es) Dihidrooxadiazinonas
DOP2020000023A (es) Nuevos derivados de quinolina
UY37460A (es) 1,2,4-triazolonas con anelación en 4 y 5
CO2019014484A2 (es) Nuevos derivados de azaquinolina
DOP2019000206A (es) 2-heteroaril-3-oxo-2,3-dihidropiridazin-4-carboxamidas
ECSP17007538A (es) 2-(morfolin-4-il)-1,7-naftiridinas
CL2021001042A1 (es) Nuevos compuestos antihelmínticos
UY37705A (es) Nuevos derivados de pirazol bicíclicos
CO2020013876A2 (es) Nuevos derivados de quinolina
UY37971A (es) Derivados de indol macrocíclicos sustituidos
UY37250A (es) Derivados macrocíclicos de indol
UY37972A (es) Derivados de indol macrocíclicos sustituidos con cloro
DOP2020000100A (es) Novedosos derivados de pirazolo-pirrolo-pirimidina como inhibidores de p2x3
UY38816A (es) Nuevos derivados de isoquinolina
UY36983A (es) Pirazolopiridinaminas sustituidas
UY37032A (es) Compuestos de heteroarilbenzimidazol